HCV Drug, Setrobuvir, Gets U.S. Patent

[Guest guest]

HCV Drug, Setrobuvir, Gets U.S. Patent

In addition to receiving fast track status from the FDA, setrobuvir has been granted a U.S. patent. Currently in a Phase IIb study, data on setrobuvir's efficacy against Hepatitis C is expected in the latter part of 2011.

US patent for Anadys Pharma covering setrobuvir

PBR Staff Writer

Published 02 June 2011

The US Patent and Trademark Office has granted Patent No 7,939,524 to Anadys Pharmaceuticals' setrobuvir (ANA598), a Direct-Acting Antiviral (DAA) in development for chronic hepatitis C virus infection (HCV).

The patent recognizes the company's intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds.

Setrobuvir, which has received fast track status from the US Food and Drug Administration, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.

Continue reading this entire article:http://processandproduction.pharmaceutical-business-review.com/news/us-patent-for-anadys-pharma-covering-setrobuvir-020611

http://www.hepatitis-central.com/mt/archives/2011/06/hcv_drug_setrob.html